Deciphering metabolic dysfunction-associated steatotic liver disease: insights from predictive modeling and clustering analysis

被引:6
|
作者
Mori, Kazuma [1 ,8 ]
Akiyama, Yukinori [2 ]
Tanaka, Marenao [1 ]
Sato, Tatsuya [1 ,3 ]
Endo, Keisuke [1 ]
Hosaka, Itaru [4 ]
Hanawa, Nagisa [5 ]
Sakamoto, Naoya [6 ,7 ]
Furuhashi, Masato [1 ]
机构
[1] Sapporo Med Univ, Sch Med, Dept Cardiovasc Renal & Metab Med, S-1,W-16,Chuo Ku, Sapporo 0608543, Japan
[2] Sapporo Med Univ, Sch Med, Dept Neurosurg, Sapporo, Japan
[3] Sapporo Med Univ, Sch Med, Dept Cellular Physiol & Signal Transduct, Sapporo, Japan
[4] Sapporo Med Univ, Sch Med, Dept Cardiovasc Surg, Sapporo, Japan
[5] Keijinkai Maruyama Clin, Dept Hlth Checkup & Promot, Sapporo, Japan
[6] Hokkaido Univ, Fac Med, Dept Gastroenterol & Hepatol, Sapporo, Japan
[7] Grad Sch Med, Sapporo, Japan
[8] Natl Def Med Coll, Dept Immunol & Microbiol, Tokorozawa, Japan
基金
日本学术振兴会;
关键词
clustering; machine learning; metabolic dysfunction-associated fatty liver disease (MAFLD); metabolic dysfunction-associated steatotic liver disease (MASLD); nonalcoholic fatty liver disease (NAFLD); CLINICAL-PRACTICE GUIDELINES; DELPHI CONSENSUS STATEMENT; ALCOHOL-CONSUMPTION; HEPATITIS-C; INDEX; RISK; INDIVIDUALS; PREVALENCE; MECHANISMS; FACTORIAL;
D O I
10.1111/jgh.16552
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and AimNew nomenclature of steatotic liver disease (SLD) including metabolic dysfunction-associated SLD (MASLD), MASLD and increased alcohol intake (MetALD), and alcohol-associated liver disease (ALD) has recently been proposed. We investigated clustering analyses to decipher the complex landscape of SLD pathologies including the former nomenclature of nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated fatty liver disease (MAFLD).MethodsJapanese individuals who received annual health checkups including abdominal ultrasonography (n = 15 788, men/women: 10 250/5538, mean age: 49 years) were recruited.ResultsThe numbers of individuals with SLD, MASLD, MetALD, ALD, NAFLD, and MAFLD were 5603 (35.5%), 4227 (26.8%), 795 (5.0%), 324 (2.1%), 3982 (25.8%), and 4946 (31.3%), respectively. Clustering analyses using t-distributed stochastic neighbor embedding and K-means to visually represent interconnections in SLDs uncovered five cluster formations. MASLD and NAFLD mainly shared three clusters including (i) low alcohol intake with relatively low-grade obesity; (ii) obesity with dyslipidemia; and (iii) dysfunction of glucose metabolism. Both MetALD and ALD displayed one distinct cluster intertwined with alcohol consumption. MAFLD widely shared all of the five clusters. In machine learning-based analyses using algorithms of random forest and extreme gradient boosting and receiver operating characteristic curve analyses, fatty liver index (FLI), calculated by body mass index, waist circumference, and levels of gamma-glutamyl transferase and triglycerides, was selected as a useful feature for SLDs.ConclusionsThe new nomenclature of SLDs is useful for obtaining a better understanding of liver pathologies and for providing valuable insights into predictive factors and the dynamic interplay of diseases. FLI may be a noninvasive predictive marker for detection of SLDs. 1 image
引用
收藏
页码:1382 / 1393
页数:12
相关论文
共 50 条
  • [41] Gut microbiota and metabolic biomarkers in metabolic dysfunction-associated steatotic liver disease
    Long, Qichen
    Luo, Fengming
    Li, Binghui
    Li, Ziyang
    Guo, Zhe
    Chen, Zhiyang
    Wu, Weimin
    Hu, Min
    HEPATOLOGY COMMUNICATIONS, 2024, 8 (03)
  • [42] METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE IS ASSOCIATED WITH LIVER FIBROSIS IN HEPATITIS C
    Elgretli, Wesal
    Shengir, Mohamed
    Sasson, Solomon
    Agnihotram, V. Ramanakumar
    Ballesteros, Luz Esther Ramos
    Deschenes, Marc
    Wong, Philip
    Chen, Tianyan
    Kronfli, Nadine
    Keeshan, Alexa
    Tandon, Saniya
    Cooper, Curtis
    Sebastiani, Giada
    HEPATOLOGY, 2024, 80 : S382 - S383
  • [43] Liver-muscle crosstalk in metabolic dysfunction-associated steatotic liver disease
    Fumo, A. R.
    Morigny, P.
    Ji, H.
    Maida, A.
    von Toerne, C.
    Alfaro, A. J.
    Motzler, K.
    Feuchtinger, A.
    Rohm, M.
    DIABETOLOGIA, 2024, 67 : S459 - S459
  • [44] The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease
    Sawada, Keisuke
    Chung, Hak
    Softic, Samir
    Moreno-Fernandez, Maria E.
    Divanovic, Senad
    CELL METABOLISM, 2023, 35 (11) : 1852 - 1871
  • [45] Racial and ethnic disparities in metabolic dysfunction-associated steatotic liver disease
    Gulati, Reeti
    Moylan, Cynthia A.
    Wilder, Julius
    Wegermann, Kara
    METABOLISM AND TARGET ORGAN DAMAGE, 2024, 4 (02):
  • [46] Metabolic Dysfunction-Associated Steatotic Liver Disease vs. Metabolic Dysfunction-Associated Fatty Liver Disease: Which Option is the Better Choice?
    Gambardella, Maria Luisa
    Abenavoli, Ludovico
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2025, 86 (02)
  • [47] Metabolic dysfunction-associated steatotic liver disease: Evolution of the final terminology
    Portincasa, Piero
    Baffy, Gyorgy
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 124 : 35 - 39
  • [48] The liver-brain axis in metabolic dysfunction-associated steatotic liver disease
    Mikkelsen, Anne Catrine Daugaard
    Kjaergaard, Kristoffer
    Schapira, Anthony H. V.
    Mookerjee, Rajeshwar P.
    Thomsen, Karen Louise
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2025, 10 (03): : 248 - 258
  • [49] The gut-liver axis and metabolic dysfunction-associated steatotic liver disease
    Demir, Muenevver
    Tacke, Frank
    Mueller-Schilling, Martina
    Schmid, Stephan
    GASTROENTEROLOGIE, 2025,
  • [50] Metabolomic Hallmarks of Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Beyoglu, Diren
    Popov, Yury V.
    Idle, Jeffrey R.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (23)